On August 21, 2017, Shire, a biotechnology company focused on developing therapies for rare diseases, announced that chief financial officer (CFO) Jeff Poulton will be leaving the company at the end of the year to serve as CFO at Indigo, a start-up company based in Boston that uses the plant microbiome to improve the productivity and sustainability of agriculture.
Poulton will continue to serve as CFO as the board conducts a formal search for his successor. During this transition period, Poulton will also remain on the company’s executive committee and board of directors, and will continue to support the company’s on-going business review.
“It has been a privilege to work for Shire and to have played a part in the exceptional growth story of such an inspirational company. It has been a difficult decision, but in departing Shire, I wanted to join a smaller organization where I can play a role in building a new company,” said Poulton, in a company press release. “As Shire finalizes the integration of Baxalta and focuses on paying down debt, this also presents a perfect time for me to begin this transition. I know I leave Shire well positioned to pursue its strategy and deliver value for shareholders, supported by a strong Finance team.”
Effective immediately, the company also announced Joanne Cordeiro as their new chief human resources officer and member of the executive committee. She takes over the role previously held by Ginger Gregory. Cordeiro joined Shire in March 2011 and has been serving as interim head of human resources since March 2017.
Source: Shire
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion for the company’s Sogroya therapy. The once-weekly treatment – also known as somapacitan – is for the replacement of endogenous growth hormone (GH) in aged children three years and older.
Medtronic is set to acquire EOFlow, the South Korea-based maker of an insulin patch pump. In its announcement of the deal Thursday, Medtronic suggested that integrating the tubeless device with its own continuous glucose monitors and meal-detection algorithm could create a new closed-loop system for largely hands-off diabetes management.
Apnimed started the year by bagging nearly $80 million in extended series C funds and the momentum has kept up, with the sleep-apnea-focused biotech nailing its goals in a phase 2 study. “For those who cannot tolerate current treatments, AD109 has the potential to be a convenient, oral pill that could improve people’s quality of life both at night and during the day.”
